AnalysisNews

OPRX today

$7.64-$1.22 (-13.81%)close Nov 13, 2026

Trend

DailyUptrend (confirmed)

4 hourStrong Bearish

1 hourBearish

15 minLeaning Bullish

5 minStrong Bearish

Daily trend turns down below $8.55

Key levels

Resistance$8.42

Resistance$7.80

Support$7.13

Support$6.57

Latest news & SEC filings

AnalystLake Street keeps Buy rating on OptimizeRx, cuts price target to $10

AnalystAnalysts lower OptimizeRx forecasts following Q3 results

AnalystB. Riley Securities keeps Buy rating on OptimizeRx, cuts target to $10.5

All OPRX news →

About OptimizeRx

OptimizeRx is a digital healthcare technology company that helps life sciences brands market to healthcare providers and patients. It offers tools for audience development, profiling, media execution, pharmacy alerts, and financial messaging, using AI and data analytics. Its customers are pharmaceutical manufacturers and their agency partners, and it operates primarily in the United States.

Based on the company's 10-K filed Mar 12, 2026.

Nasdaq · Industrials

OptimizeRx Corp (OPRX)

$7.53-1.34 (-15.11%)
WATCHLISTGrade: ARisk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
7.998.458.909.367.53Oct 13Oct 21Oct 29Nov 6
High8.69
Low7.22
Open8.43
Volume279K
Avg Vol179K
VWAP7.80
30d High9.82
30d Low7.53
30d Chg-13.65%

What Is the Price Target for OPRX?

SEPT Low Target

$7.00

SEPT Mid Target

$10.75

SEPT High Target

$11.00

Analyst Consensus

$10.75

Current: $8.36Upside: +28.6%Confidence: 85%Method: Analyst Consensus

Is OPRX a Buy or Sell Right Now?

81
Investability Score
WATCHLIST12-18 months
News summary · last 30 days
Nov 12▲ UpEarningsUpgrade5 articles
OptimizeRx shares surged 32.39% to close at $8.87 after the company reported its third-quarter 2026 results and updated full-year 2026 guidance. Following the earnings release, analysts adjusted their views: Lake Street and B. Riley Securities both maintained Buy ratings while trimming their price targets to $10 and $10.50, respectively, though other analysts lowered their forecasts on the Q3 results. The strong price move suggests investors focused on the earnings report itself rather than the mixed analyst revisions. Despite the target cuts, the maintained Buy ratings from two firms signal continued positive sentiment, and the stock's close near its daily high of $8.95 indicates upward momentum.
Nov 11▼ DownEarningsGuidance cut2 articles
OptimizeRx shares fell 4.79% to close at $8.95 after the company cut its FY2026 sales outlook to $87M-$93M from $95M-$100M, with the new midpoint below the $96.23M analyst estimate. The reduced guidance overshadowed a stronger-than-expected third quarter, in which adjusted profit topped forecasts and revenue also beat consensus. The stock traded between $8.85 and $9.83 on volume of 336,855 shares. While the Q3 beat is a positive signal, the lowered forward outlook weighed on sentiment and drove the shares lower.
Critical news
Nov 11HIGHEarnings: growth/beat

Thesis

  • •Revenue growing 18.8% YoY with ACCELERATING trend — accelerating momentum.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OPRX.

Start Free Trial →

Is OPRX Overvalued or Undervalued?

Valuation Verdict

UNDERVALUED

Methods Used

P/E Forward, P/B, Analyst Consensus

Fair Value

$13.95

57

Moat Score

NARROW

8/9

Piotroski Score

2.6

Altman Z-Score

What Is Smart Money Doing with OPRX?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Recent Insider Activity

NameTitleTypeSharesValueDate
D'Silva Andrew J.officerSale1,432$11KSep 1, 2026
KLEMA CATHYdirectorBuy34,517-Jun 9, 2026
Lang James PauldirectorBuy34,517-Jun 9, 2026
Presti Mariyamma VarghesedirectorBuy17,258-Jun 9, 2026
Spangler Patrick DdirectorBuy34,517-Jun 9, 2026
Vos Ellen O'ConnordirectorBuy34,517-Jun 9, 2026
WASSON GREGORY DdirectorBuy34,517-Jun 9, 2026
Greco TheresaofficerSale914$5KMay 15, 2026
Greco TheresaofficerSale879$5KMay 15, 2026
Silvestro Stephen LofficerSale5,219$27KMay 15, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

OPRX Growth Story

Revenue YoY

18.8%

3yr Revenue CAGR

20.6%

EPS Growth YoY

124.55%

FCF Growth YoY

290.6%

Revenue Trend

ACCELERATING

Dark Pool Trades for OPRX

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for OPRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

TimePriceSizeValueSide
18:55:13$7.541,000$$8KMIDPOINT
18:53:45$7.581,000$$8KMIDPOINT
17:06:27$7.391,000$$7KSELL
15:56:30$7.591,000$$8KBUY
15:16:23$7.801,183$$9KMIDPOINT

5 dark pool trades shown · $$39K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Options Flow for OPRX

PREVIEW

SEPT Investing provides real-time options flow tracking for OPRX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.

TypeStrikeExpiryDTEPremiumSizeTrade
CALL$7.5Nov 207$$451SWEEP
CALL$7.5Nov 207$$54012SWEEP
CALL$7.5Nov 207$$451SWEEP
CALL$7.5Nov 207$$451SWEEP
CALL$7.5Nov 207$$451SWEEP

5 options trades shown · 100% calls

Unusual activity, GEX levels, max pain, and dealer positioning

See full options flow

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for OptimizeRx Corp (OPRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (9 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

OPRX — frequently asked questions

What is OPRX stock price today?

OptimizeRx Corp (OPRX) is at $7.64, down 13.81% (-$1.22) at the Nov 13, 2026 close.

Why is OPRX stock down today?

Nov 12, 2026: OptimizeRx shares surged 32.39% to close at $8.87 after the company reported its third-quarter 2026 results and updated full-year 2026 guidance. Following the earnings release, analysts adjusted their views: Lake Street and B.

What is the OPRX price target?

The average analyst price target for OPRX is $10.75, ranging from $7 to $11, based on 6 analysts. Latest: Lake Street maintains on Nov 12, 2026.

What do analysts rate OPRX?

Analyst ratings for OPRX: 0 Buy, 6 Hold, 0 Sell — consensus Hold.

Did OPRX beat earnings?

OPRX last reported on Nov 11, 2026: EPS $0.20 vs $0.17 expected — a beat of 17.6%.

What is OPRX's P/E ratio?

OPRX trades at a P/E of 37.3 vs a Industrials average of 25.5.

Does OPRX pay a dividend?

OPRX does not currently pay a dividend.

How much debt does OPRX have?

OptimizeRx Corp reported $20M of debt and $24M of cash (Jun 30, 2026).

What are OPRX support and resistance levels?

Support: $7.13, $6.57, $5.72. Resistance: $7.80, $8.42, $9.18.

What are insiders doing with OPRX?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on OPRX?

Nov 12, 2026: Lake Street keeps Buy rating on OptimizeRx, cuts price target to $10 · Nov 12, 2026: Analysts lower OptimizeRx forecasts following Q3 results · Nov 12, 2026: B. Riley Securities keeps Buy rating on OptimizeRx, cuts target to $10.5